TY - JOUR
T1 - Psychiatric disorders in a patient with persistent developmental stuttering
AU - Dias, Fernando Mac Hado Vilhena
AU - Pereira, Patrícia Matos
AU - De Proença Doyle, Flavia Costa
AU - Teixeira, Antônio Lúcio
PY - 2011/9
Y1 - 2011/9
N2 - Persistent developmental stuttering (PDS) is a common disorder of speech with no identifiable cause. Psychiatric disorders appear to be related and influence clinical manifestation of PDS. In this case report, we present the clinical evolution of 1 PDS patient submitted to pharmacological treatment with fluoxetine and speech therapy intervention. At the end of 12 weeks of treatment, she evolved from 28 at Beck Depression Inventory; 32 in the Hamilton Scale for Anxiety; 43 and 47, respectively, in the anxiety and avoidance components of the Liebowitz Social Anxiety Scale; and severe speech impairment according Iowa Scale, to 12 at Beck Depression Inventory; 8 at Hamilton Scale for Anxiety; 25 and 21 at Liebowitz Social Anxiety Scale anxiety and avoidance components, respectively; and moderate speech impairment. Diagnosing and treating psychiatric symptoms in addition to speech therapy appears to be the best therapeutic approach.
AB - Persistent developmental stuttering (PDS) is a common disorder of speech with no identifiable cause. Psychiatric disorders appear to be related and influence clinical manifestation of PDS. In this case report, we present the clinical evolution of 1 PDS patient submitted to pharmacological treatment with fluoxetine and speech therapy intervention. At the end of 12 weeks of treatment, she evolved from 28 at Beck Depression Inventory; 32 in the Hamilton Scale for Anxiety; 43 and 47, respectively, in the anxiety and avoidance components of the Liebowitz Social Anxiety Scale; and severe speech impairment according Iowa Scale, to 12 at Beck Depression Inventory; 8 at Hamilton Scale for Anxiety; 25 and 21 at Liebowitz Social Anxiety Scale anxiety and avoidance components, respectively; and moderate speech impairment. Diagnosing and treating psychiatric symptoms in addition to speech therapy appears to be the best therapeutic approach.
UR - http://www.scopus.com/inward/record.url?scp=80053079693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053079693&partnerID=8YFLogxK
U2 - 10.1097/WNF.0b013e31822b9ead
DO - 10.1097/WNF.0b013e31822b9ead
M3 - Article
C2 - 21926485
AN - SCOPUS:80053079693
SN - 0362-5664
VL - 34
SP - 199
EP - 200
JO - Clinical neuropharmacology
JF - Clinical neuropharmacology
IS - 5
ER -